J&J awaits jury verdict over Risperdal patient's breast development

Did Johnson & Johnson ($JNJ) hide Risperdal's potential to trigger breast growth in boys? Or did the drugmaker adequately disclose the potential side effect? A Philadelphia jury is literally out deliberating on these two questions.

After a trial lasting almost a month, lawyers for both sides summed up their arguments Friday. On the one side is a young man who developed breasts--size 46DD, according to Bloomberg--while taking J&J's antipsychotic drug. His attorneys argue that J&J's own data shows that the company knew about the risk, but didn't warn doctors or patients for years.

"When a pharmaceutical company is acting reasonably and prudently they investigate it, they report it, they tell the FDA, they tell the world," said the plaintiff's lawyer, Thomas Kline of Kline & Specter, as quoted by The Legal Intelligencer. "Nobody knew all this risk, except the insiders."

On the other is J&J's Janssen unit and its Risperdal brand, one of the company's top-selling drugs for years before it lost patent protection in 2012. Janssen's lawyers say the company's warnings were on the up-and-up and that the plaintiffs haven't proven Risperdal caused the young man's breast development.

The plaintiff's case represents "the height of cherry-picking" of scientific data, Janssen lawyer Diane Sullivan said during closing arguments. Sullivan also tried to discredit the plaintiffs' expert witnesses--including former FDA commissioner David Kessler--by calling them "regulars on the litigation circuit."

It's just one of some 1,250 similar lawsuits pending against J&J, which has already settled thousands of claims that Risperdal caused weight gain and diabetes. The company has also been fighting state court lawsuits alleging that J&J committed fraud when marketing Risperdal.

In 2013, J&J pleaded guilty to a misdemeanor violation of the Food, Drug and Cosmetic Act and agreed to pay $2.2 billion to settle off-label marketing allegations leveled by whistleblowers and backed by the U.S. Justice Department. According to the settlement, J&J allegedly pushed Risperdal to treat children and adolescents years before the drug was approved for pediatric use.

In addition to the $2.2 billion settlement J&J made in the federal whistleblower lawsuit, it also settled off-label marketing claims with 36 states and the District of Columbia over the marketing of Risperdal that topped $180 million--then with Texas for $158 million more.

J&J has also successfully fought off some verdicts, though. J&J lost a $1.2 billion verdict in Arkansas over similar claims, but the Arkansas Supreme Court tossed out the verdict. J&J also deflected a $257 million award in Louisiana after convincing the top court in that state that its marketing had not violated a state law.

- read The Legal Intelligencer article
- get more from Bloomberg

Special Report: Pharma's Top 11 Marketing Settlements

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.